In view of the fact that CYCLON acts as an independent tumour growth driver in MYC-driven lymphoma, and that MYC and CYCLON overexpression controls a JQ1-sensitive Rituximab resistance pathway, we next wished to investigate the possible links between CYCLON activity and BET bromodomain inhibition. Here, MYC is linked to lymphoma.